Polynovo (ASX:PNV) Beta: 2.3261 (As of Jun. 26, 2026)


ASX:PNV Polynovo Ltd ASX:PNV
76 GF Score
Price A$0.95
GF Value A$3.24
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Polynovo Beta?

Polynovo ASX:PNV +1.07% 76 Beta is 2.3261 as of Jun. 26, 2026. GuruFocus rates ASX:PNV with a GF Score™ of 76/100 and a GF Value™ of A$3.24 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Polynovo's Beta is 2.3261.


Polynovo  (ASX:PNV) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Polynovo Beta Related Terms


Polynovo Beta Historical Data

* Premium members only.

The historical data trend for Polynovo's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polynovo Beta Chart

Polynovo Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.94 1.59 1.66 1.80 3.09

Polynovo Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.85 1.80 1.86 3.09 3.20

ASX:PNV vs ABT, SYK, MDT: Beta Comparison

For the Medical Devices subindustry, Polynovo's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Polynovo Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's Beta distribution charts can be found below:

* The bar in red indicates where Polynovo's Beta falls into.


ASX:PNV
76GF Score
Polynovo Ltd ASX:PNV
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polynovo Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.3261 mean?
Polynovo (ASX:PNV) has a Beta of 2.3261 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Polynovo and its competitors.
Is Polynovo's Beta too high?
Polynovo's current Beta is 2.3261. Overall, Polynovo has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's Beta compare to ABT and SYK?
Polynovo's Beta of 2.3261 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Polynovo and its competitors. Polynovo's current Beta is 2.3261. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (ASX:PNV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$3.24, compared to a current price of A$0.95 — trading 70.8% below its estimated fair value. The current Beta is 2.3261. Polynovo's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Polynovo (ASX:PNV), the current Beta is 2.3261 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Polynovo (ASX:PNV) Overvalued in 2026?

Based on GuruFocus' analysis, Polynovo stock appears to be undervalued. The current stock price of A$0.95 is trading 70.8% below its estimated GF Value™ of A$3.24. GuruFocus considers Polynovo to be Significantly Undervalued.

Key valuation signals for ASX:PNV:

  • Beta: 2.3261
  • GF Value™: A$3.24 vs. price of A$0.95 (70.8% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the ASX:PNV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Polynovo Business Description

Other Exchanges CALZF:USAMFJ:Germany
Address 320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
76GF Score

Get the complete analysis for ASX:PNV

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.95
Price
A$3.24
GF Value